14 results
6-K
EX-99.3
ACIU
AC Immune SA
21 Mar 19
Current report (foreign)
7:44am
on rewarding the delivery of outstanding and sustainable results without inappropriate risk-taking.
In each of the years from 2016 - 2018, the Company engaged
6-K
EX-99.3
ACIU
AC Immune SA
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am
the delivery of outstanding and sustainable results without inappropriate risk-taking.
In 2018 and 2019, the Company engaged a reputable compensation
6-K
EX-99.4
ACIU
AC Immune SA
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
shareholders. In addition, compensation elements are focused on rewarding the delivery of outstanding and sustainable results without inappropriate
6-K
EX-99.4
ACIU
AC Immune SA
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
on rewarding the delivery of outstanding and sustainable results without inappropriate risk-taking.
In 2020 and 2019, the Company engaged a reputable
6-K
EX-99.1
ACIU
AC Immune SA
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
the performance year. Long - Term Incentive (equity) awards are designed to drive sustainable long - term contribution to align compensation
6-K
EX-99.1
tcb2ahf3ihs69
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
6-K
EX-99.1
76uoxpgbu5k bvcet
21 May 21
Notice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1
8:55am
20-F
p48akj
17 Mar 17
Annual report (foreign)
12:00am
- Prev
- 1
- Next